23andMe, Inc. (23andMe) is a personal genomics and biotechnology company that leverages machine learning (ML) technology to provide DNA analysis services.

Scope

The report provides information and insights into 23andMe, Inc.'s, including –

– Overview of the company and its product offering

– Detailed insight into its business model, company type and headquarter

– Information on funding

– Biography of top management

Reasons to Buy

– Gain insights into 23andMe’s business operations.

– Gain insights into funding and partnerships

– Gain understanding about its technology focus.

Key Players

Almirall

S.A. (ALM)

Lark Health

iHeartRadio

GlaxoSmithKline (GSK)

University of Queensland

Sequoia Capital

Euclidean Capital

Altimeter Capital

Wallenberg Foundation

Fidelity Management & Research Company

Casdin Capital

Table of Contents

Table of Contents

Company Overview

Technology Focus

Product Overview

Partnerships & Funding

Key Employees

Appendix

Frequently Asked Questions

Enquire Before Buying
$350

Can be used by individual purchaser only

$1050

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 (0) 20 7947 2960

GDPR + CCPA Compliant

Personal and transaction information are kept safe from unauthorised use.

Recently Viewed Reports

Looking to stay on top of industry & market trends?

Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.

Technology
New
New
How Digital Transition is Reshaping Capital Markets
$1495 | August 12, 2022
Technology
New
New
3M Company – Enterprise Tech Ecosystem Series
$1495 | August 12, 2022
Technology
New
New
Marathon Petroleum Corp – Enterprise Tech Ecosystem Series
$1495 | August 12, 2022